See the DrugPatentWatch profile for Humira
Humira, a widely prescribed medication for autoimmune diseases like rheumatoid arthritis and Crohn's disease, has been a subject of significant patent activity and legal challenges. The drug's active ingredient is adalimumab [1].
When do Humira's main patents expire?
The primary patents covering Humira and its method of use have largely expired, allowing for the introduction of biosimilars in various markets. For instance, in the United States, key patents expired around 2023, with earlier expirations in other regions like Europe [1][2].
Why are companies challenging Humira's patents?
Patent challenges are a common strategy for pharmaceutical companies aiming to introduce generic or biosimilar versions of a drug before its official patent expiry. These challenges can involve seeking to invalidate existing patents or arguing that their own products do not infringe upon them. Such strategies are designed to gain early market access and capture market share [3].
How does the launch of Humira biosimilars work?
Biosimilars are highly similar versions of already-approved biologic medicines, with no clinically meaningful differences in terms of safety, purity, and potency. Once the relevant patents expire and regulatory approvals are obtained, biosimilar manufacturers can market their products, often at a lower cost than the originator drug [4].
What is the impact of biosimilars on Humira's market?
The introduction of biosimilars has led to increased competition and price reductions for adalimumab. This can make the treatment more accessible to a wider patient population and reduce overall healthcare costs [4].
Who are the main competitors making Humira biosimilars?
Several pharmaceutical companies have developed and launched biosimilar versions of adalimumab. Notable examples include AbbVie's own biosimilar, as well as those from manufacturers such as Amgen, Boehringer Ingelheim, Coherus BioSciences, Fresenius Kabi, and Organon [1][5].
What are the different types of patents involved with Humira?
The patent landscape for a drug like Humira is complex and can include patents for the active molecule (adalimumab), methods of manufacturing, specific formulations, and methods of use for treating particular conditions. Different patents may have staggered expiry dates [3].
Can biosimilars enter the market before patent expiry?
While patent expiry is a primary driver for biosimilar entry, legal disputes and settlement agreements can sometimes influence timelines. In some cases, biosimilar manufacturers may settle with the originator company to agree on a launch date, which might be before the ultimate expiry of all patents but after a negotiated period [3].
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/p/adalimumab
[3] https://www.drugpatentwatch.com/blog/adalimumab-patent-litigation
[4] https://www.drugpatentwatch.com/blog/humira-biosimilar-launch-strategy
[5] https://www.drugpatentwatch.com/biosimilars/adalimumab